Dr. Hoffman is the Chief Business Officer of Athos Therapeutics Inc. Prior to Athos, he was the Senior Vice President of Business Development and Technology Transfer at the Lundquist Institute for Biomedical Innovation at the Harbor-UCLA Medical Center, a research institute with over 400 scientists and 600 research projects. Keith oversaw all commercialization, licensing, startup company formation, and intellectual property, as well as bioscience incubator and biotechnology park developments. Before the Lundquist Institute, he was part of the founding team at Advera Health Analytics where he developed and helped monetize big data platforms that provide real world side effect data on all FDA approved drugs. Dr. Hoffman has also held senior management roles (COO, CBO, VP) in business, corporate, science, and intellectual property development for biotechnology, healthcare data, medical device, and consumer product companies. His extensive deal sheet includes financing, licensing, sponsored research, sales and marketing, collaborations, mergers, and patent litigation. He has published 30 academic papers, 20 white papers, and has drafted over 70 patent applications across various scientific disciplines. Dr. Hoffman earned both his B.S. in Biology and Ph.D. in Neuropharmacology from UC Irvine in the world-renowned laboratory of Dr. Gary Lynch. His research at Irvine focused on the molecular basis of learning and memory with an emphasis on how neural cell adhesion molecules may modulate synaptic architectures.
